BSE filing, NSE: IOLCP. Summary written from the filing by ALFA Finder's alert engine.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹184.93
- Market cap
- ₹5,428 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 32.3×Sector 48.7×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
IOL Chemicals and Pharmaceuticals Regulatory Approval
IOL Chemicals and Pharmaceuticals Limited received EU-REACH registration for its product 'Triacetin', enabling the company to export this product to countries in the European Union.
IOL Chemicals and Pharmaceuticals Other Announcement
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.
IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
- Call
- Guides 20% growth
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹350 Cr Investment
IOL Chemicals and Pharmaceuticals Ltd will expand Ibuprofen capacity by 6,000 MTPA. The project, requiring a ₹350 Crore investment, is expected to be commercialized by December 2027.
- Value
- ₹350.0 Cr
- Execution
- December 2027
- manufacturing capacity
- 6000.0 MTPA
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹495 Cr Investment
IOLCP announces three capacity expansions at Barnala: 6,000 MTPA Ibuprofen unit, CDMO formulation facility, and specialty chemicals tolling plant. Total investment ₹495 Crore funded via internal accruals.
- Value
- ₹495.0 Cr
- ibuprofen manufacturing capacity
- 6000 MTPA
Other other announcement announcements
All →Three M Paper Boards Other Announcement
Three M Paper Boards filed its Reg 13(3) investor grievance report. All complaint categories for the quarter show NIL figures.
Manika Plastech Other Announcement
Manika Plastech intimated a change in its CIN from U- to L-prefixed code following its September 2026 listing. This is a routine MCA registry update with no transactional or business substance.
Symphony Other Announcement
Symphony Limited informed exchanges that management will appear on CNBC Bajar Gujarati on October 30, 2026, to discuss Q2 financial results and business outlook. No new business information is disclosed in this scheduling notice.
Decorous Investment & Trading Co Other Announcement
Decorous Investment submitted quarterly compliance certificates for the quarter ended 30.09.2026. The filing holds only routine SEBI LODR disclosures with no transactional or financial substance.
STL Networks Other Announcement
The Monitoring Agency reported Rs. 2 Crore utilization of Preferential Issue proceeds, with no deviations from objects. The report covers the quarter ending September 30, 2026.
HEG Advanced Materials Other Announcement
HEG Advanced Materials Limited has intimated the exchange regarding the change of its Corporate Identification Number (CIN) following an approved scheme of arrangement.